Analysts are optimistic about Verve Therapeutics, predicting...
Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.
Rainbows and Unicorns: Verve Therapeutics, Inc. (NASDAQ:VERV) Analysts Just Became A Lot More Optimistic
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment